Systemic adverse events from inhaled corticosteroids self-reported by asthma patients: A “real-life” cross sectional study  by Pinto, C.R. et al.
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The  present  study  showed  that  inhaled  antimicrobial
rapy  is  an  attractive  alternative  to  systemic  admin-
ration  because  it  is  associated  with  main  advantages
h  as  ability  to  achieve  high  concentrations  of  antimi-
bials  in  sputum  and  in  the  bronchial  and  pulmonary
sue;  and  ability  to  reach  minimum  inhibitory  con-
ntrations  at  lower  dosages  compared  with  intravenous
mulations.
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adverse  events  was  assessed  by  using  the  Spearman  Rho
correlation  coefﬁcient.
Of  the  65  patients  who  were  evaluated,  54  (83.1%)  were
female,  with  an  average  age  of  49.7  [SD  =  12.2]  years.  Of
the  total,  29  (44.6%)  patients  were  taking  high  doses  of  ICS
(budesonide  >  800  mcg/day),  where  the  median  daily  dose  of
ICS  was  800  mcg.  The  average  treatment  duration  was  38.2
[30.7]  months.  Sixty  (92.3%)  patients  reported  at  least  one
systemic  adverse  event,  and  31  (47.7%)  patients  reported
daily  symptoms.  A  total  of  213  events  were  reported  with  a
median  of  3.0  per  patient  (Table  1).
All  patients  were  taking  ICS  plus  long-acting  2-agonist
(87.7%  formoterol  plus  budesonide,  12.3%  salmeterol  plus
ﬂuticasone).  Thirty-six  (55.4%)  patients  received  treatment
consistent  with  moderate  asthma  and  29  (44.6%)  received
high-intensity  treatment,  consistent  with  severe  asthma.Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A,
et al. Acceleration of lung disease in children with cystic ﬁbro-
sis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol.
2001;32:277--87.
Michalopoulos AS. Aerosolized antibiotics: the past, present and
future, with a special emphasis on inhaled colistin. Expert Opin
Drug Deliv. 2012;9:493--5.
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-
cystic ﬁbrosis bronchiectasis: a systematic review. Eur Respir J.
2014;44:382--93.
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rrent  guidelines  recommend  the  use  of  inhaled  corticoste-
ds  (ICS)  for  patients  with  moderate  to  severe  persistent
hma  treatment  maintenance.1 However,  the  use  of  high
ses  for  long  periods  potentially  increase  systemic  adverse
ents.2,3 A  disconnection  between  clinician  estimates  of
 side  effects  and  the  prevalence  reported  by  patients  has
viously  been  reported.4 Furthermore,  there  is  evidence
t  many  asthmatic  patients  prefer  not  to  discuss  or  spon-
eously  report  their  concerns  regarding  ICS  adverse  events
th  their  health  care  professionals.5,6 The  self-reported
estionnaires  provide  an  efﬁcient  method  of  accessing
ormation  about  adverse  events.7,8 We  describe  systemic
verse  events  associated  with  the  use  of  ICS  in  patients
th  moderate  to  severe  asthma  using  this  technique.
Subjects  included  were  18  or  older,  had  moderate  or
ere  persistent  asthma,1 had  been  regularly  using  ICS  for  6
more  months  between  June  of  2010  and  February  of  2011
d  presented  at  the  Pharmaceutical  Assistance  Service  of
 Pneumology  Reference  Outpatient  Clinic  of  the  Federal
iversity  of  Bahia,  in  Salvador,  Bahia.  Patients  taking  oral,
renteral,  ocular  or  topical  corticosteroids  within  the  pre-
us  three  months  were  excluded.
A  pilot  study  assessing  questionnaire  structure,  content
d  clarity  generated  data  for  an  expert  team  who  reviewed
ults  and  suggested  changes.  The  self-report  question-
ire,  covered  the  previous  14  days  using  a  4-point  Likert
le  (0  =  never;  1  =  occasionally;  2  =  most  days;  3 =  daily)  and
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ptured  patient’s  perceptions  regarding  the  ICS  systemic
verse  events  (dry  skin,  swollen  face,  easy  bruising,  mood
ings,  night  sweating,  brittle  breaking  nails,  hair  loss  and
ected  vision).  The  total  score  ranged  from  0  (no  percep-
n  of  events)  to  24  (maximum),  this  score  was  standardized
score  from  0  (no  events)  to  100  (worst).
The  difference  in  the  intensity  of  systemic  adverse  events
tween  the  two  dosage  groups  in  relation  to  the  total  score
cumulated)  was  analyzed  using  t-test.  The  correlation
tween  duration  of  ICS  use  and  the  number  of  systemicmographic  characteristics  were  similar  between  the  two
ups.  The  prevalence  of  vision  disturbances  and  dry  skin
s  greater  in  the  high-intensity  treatment  group  (p  <  0.05)
ggesting  a  causal  relationship.  Asthma  severity  (r  =  0.274;
 0.027)  and  ICS  use  duration  (r  =  0.361;  p  =  0.003)  were
rrelated  with  the  number  of  systemic  adverse  events.  Fur-
rmore,  patients  who  used  ICS  for  longer  periods  reported
re  face  swelling  (p  =  0.04)  and  dry  skin  (p  = 0.002).
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Table  1  Frequency  of  systemic  adverse  events  reported  by  65  moderate  or  severe  asthmatics  of  Pneumology  Reference  Out-
patient Clinic  of  the  Professor  Edgard  Santos  University  Hospital  Complex  of  the  Federal  University  of  Bahia  between  June  2010
and February  2011.
Adverse  event Frequency  Total  n  (%)
Occasionally  n  (%)  Most  of  the  days  n  (%)  Daily  n  (%)
Night  sweating  4  (6.2)  7  (10.8)  19  (29.2)  30  (46.2)
Brittle breaking  nails  6  (9.2)  10  (15.4)  13  (20)  29  (44.6)
Vision affected  8  (12.3)  9  (13.8)  12  (18.5)  29  (44.6)
Dry skin 8  (12.3) 9  (13.8) 15  (23.1)  32  (49.2)
Mood swings 9  (13.8) 12  (18.5) 12  (18.5) 33  (50.8)
Hair loss 3  (4.6) 8  (12.3) 13  (20) 24  (36.9)
Bruising easily  7  (10.8)  6  (9.2)  7  (10.8)  20  (30.8)
Swollen face  7  (10.8)  4  (6.2)  5  (7.7)  16  (24.6)
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Figure  1  Intensity  of  systemic  adverse  event  perception  by
daily dosage  group  as  measured  by  total  score  (0--100)  of  the
adverse  events  questionnaire.
Patients  taking  high-intensity  treatment  presented  a  greater
number  of  systemic  adverse  events  than  those  taking  lower
doses  (3.9  ±  15.3  and  2.8  ±  14.9,  respectively;  p  =  0.028).
The  total  score  of  the  adverse  event  assessment  ques-
tionnaire  also  showed  a  statistically  signiﬁcant  increase  in
the  intensity  of  the  systemic  events,  observed  with  the
increase  of  the  daily  dose  of  ICS  (Fig.  1).  Our  ﬁndings  of
elevated  perception  of  systemic  events  induced  by  ICS  cor-
roborate  the  data  of  previous  studies  that  used  self-report
questionnaires.4,7
Although  the  small  sample  size  could  be  limitation,  the
importance  of  the  study  is  to  raise  the  possible  dose-related
association  with  ICS.  We  cannot  rule  out  the  possibility  of
our  ﬁndings  be  biased  in  terms  of  older  age  and  female  gen-
der.  However,  we  identiﬁed  the  fact  that  the  prevalence
of  vision  disturbances  and  dry  skin,  events  associated  with
advanced  age,  was  greater  in  the  high-intensity  treatment
group  (p  <  0.05)  suggesting  a  dose  dependent  association
that  could  not  be  explained  by  age  or  gender  because  these
two  features  were  similar  between  the  groups.  Although
features)  and  others  concomitant  drugs  cannot  be  total
excluded.
This  study  shows  that  individuals  with  moderate  to  sever
asthma,  assessed  in  real  life,  have  a  high  perception  of  sy
temic  adverse  events,  including  mood  swings  and  dry  skin
Strategies  to  detect  and  manage  ICS  adverse  events  in  clin
ical  practice  may  be  useful  in  order  to  improve  the  resul
of  pharmacotherapy  for  asthma.
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Pulmonary tuberculosis
epidemiology in Coimbra’s
District (2000--2011):
Information is essential to
understand high risk groups
Dear  Editor,
Tuberculosis  (TB)  knows  no  boundaries.  It  is  a  disease
not  only  of  the  patient  as  an  individual,  but  also  of  the
community  itself.  Its  control  has  always  transcended  the
conventional  strategies  and  made  it  necessary  to  under-
stand  the  individual  interaction  with  the  social  and  economic
culture.  In  order  to  do  so,  the  surveillance  programs  provide
support  for  evaluation  of  the  burden  of  TB,  the  effectiveness
of  its  control  and  suggested  hypotheses  for  further  research.
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tendency  until  2010  (Fig.  1).  The  study  population  enrolled
was  72.3%  male  (402/556).  In  2000  and  2011  the  median  age
was  40  and  47  years  respectively.  Only  in  2000,  2005  and
2006  there  were  patients  reported  under  18  years  of  age
(14,  6  and  5,  respectively).  The  annual  ratio  between  men
and  women  peaked  at  2.9:1  in  2004,  and  was  lowest  at  0.9:1
in  2011.
There  were  88.1%  (490/556)  national  and  11.9%  (66/556)
foreign-born  patients  reported.  The  median  age  was  44
years,  and  35  years,  respectively.  Most  of  the  foreign-
born  patients  were  from  former  Portuguese  colonies:  Angola
(33.3%),  Mozambique  (10.6%),  Cape  Verde  (9.1%),  and
Guinea-Bissau  (6%).
The  three  most  frequent  co-morbidities  were  human
immunodeﬁciency  virus  (HIV)  co-infection  (32/169),  dia-
betes  (38/556),  hepatitis  C  virus  infection  (35/556).
HIV  status  was  registered  in  only  30.4%  (169/556)  of  the
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Alcohol disorder Drug addiction Tobacco smokerConsidering  the  importance  of  active  case  ﬁnding  in  low
idence  settings,  an  epidemiological  study  was  developed
assess  high  risk  groups  for  Pulmonary  TB  cases  notiﬁed
d  residing  in  Coimbra  District  (Portugal),  between  2000
d  2011,  contributing  to  a  proper  understanding  for  pro-
mmatic  approaches.
The  study  was  designed  as  a  retrospective  cohort.  It  was
rried  out  at  the  Respiratory  Diagnostic  Centres  of  Coimbra
d  Figueira  da  Foz.  There  were  556  cases  retrospectively
rolled,  of  which  only  339  were  identiﬁed  with  antimicro-
l  susceptibility  testing  on  their  clinical  records.
Various  parameters  were  analyzed,  such  as  demographic,
ioeconomic,  and  associated  diseases  data,  using  descrip-
e  statistics.
The  incidence  was  the  highest  in  2004  (14.2/100  thou-
d).  After  2005,  it  reverted  to  its  previous  decreasing
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)ure  1  Pulmonary  tuberculosis  incidence  rate,  in  Coimbra’s
trict,  2000--2011.
Fig
adtients  reported.  Of  the  169  patients,  39  were  HIV  positive,
whom  12  were  foreign-born.
The  prevalence  of  alcohol,  tobacco  smoke  and  drug  abuse
s  23.6%  (130/556),  37.3%  (206/556)  and  8.7%  (48/556)
pectively.  The  annual  prevalence  of  alcohol  disorder
aked  in  2007  (18/43).  Among  patients  with  drug  addic-
n,  their  prevalence  peaked  in  2006  (6/44).  Among  tobacco
okers  there  was  a  regular  trend,  which  peaked  in  2009
/33)  (Fig.  2).
The  highest  annual  prevalence  among  residents  in  com-
nity  shelters,  homeless,  and  prisoners,  was  13.2%  (5/38)
2008,  6.8%  (3/44)  in  2006  and  9.7%  (6/62)  in  2004,  respec-
ely.
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)ure  2  Proportion  of  pulmonary  tuberculosis  patients  by
dictive  behaviors,  on  Coimbra’s  District,  2000--2011  (N  =  556).
